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Abstract
Introduction In 1998, the first Japanese practice guidelines
on osteoporosis was published. It has been updated several
times, with the most recent being the full-scale 2011 edition
and its abridged edition. The present guidelines provide
information for the managements of primary osteoporosis
in postmenopausal women and men over 50 years old, a
summary of the evidence for the treatment of secondary
osteoporosis, and a summary of the evidence for the pre-
vention of osteoporosis in younger people.
A Report of the Committee for Developing Guidelines for Prevention
and Treatment of Osteoporosis: Japan Osteoporosis Society, Japanese
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Method The present Executive Summary is primarily based
on the content of the 2011 Japanese abridged edition. One of
the key changes is revision of the criteria for initiation of
pharmacological treatment, along with an introduction of
the fracture risk factors used in FRAX®. Key figures and
tables were selected from the Japanese abridged edition and
a reference list was added.
Result and conclusions The essential points of the Japanese
practice guidelines on osteoporosis were translated into
English for the first time. It is hoped that the content of
the guidelines becomes known throughout the world.
Keywords Criteria for initiation of pharmacological
treatment . Diagnosis of osteoporosis . Fracture risk
assessment . Prevention of osteoporosis . Secondary
osteoporosis . Treatment of osteoporosis
Preamble
In 1998, we published the “Guidelines for (Pharmacological)
Treatment of Osteoporosis 1998” under the name of the
Working Group for Developing Guidelines for Osteoporosis
in the Osteoporosis Research Project supported by the Minis-
try of Health and Welfare (present-day Ministry of Health,
Labor, and Welfare) of Japan. Although they were the first
Japanese guidelines for the diagnosis and treatment of osteo-
porosis and also set a precedent for evidence-based practice
guidelines in Japan, there were few effective therapeutic
agents for osteoporosis available in Japan at that time. The
1998 edition was updated in 2002.
There has been tremendous change in the field of osteopo-
rosis inside and outside Japan since that update. Addressing
osteoporosis has become a more urgent issue also in Japan
because of its fast-aging society. Therefore, we published the
comprehensive “Guidelines for Prevention and Treatment of
Osteoporosis 2006” under the name of the Committee for
Developing Guidelines for Prevention and Treatment of Os-
teoporosis 2006, an ad hoc organization comprising the Japan
Osteoporosis Society, Japanese Society for Bone and Mineral
Research, and Japan Osteoporosis Foundation. Emphasizing
prevention, covering secondary osteoporosis, presenting the
criteria for initiation of pharmacological treatment, and grad-
ing the recommendation for each therapeutic agent, these
guidelines were highly rated in the medical and clinical
arenas. Immediately thereafter we published an abridged edi-
tion to disseminate the content of the 2006 Guidelines to a
greater number of doctors and healthcare professionals.
In late 2011, the 2006 Guidelines and its abridged edition
were updated. Key changes are as follows: profile of the
research progress on bone quality, revision of the criteria for
initiation of pharmacological treatment (associated with the
re-examination of the risk factors for fracture and introduc-
ing FRAX®), more detailed descriptions about secondary
osteoporosis (including new information on the relationship
between lifestyle-related diseases and fracture risk), evalua-
tion of new therapeutic agents, and bone metabolic markers
covered by public insurance. The present Executive Sum-
mary is primarily based on the content of the updated 2011
Japanese abridged edition. Only the most key figures and
tables were selected from the Japanese abridged edition and
a reference list was added. We hope this Executive Summa-
ry contributes to the advancement of medical care for oste-
oporosis in Asia and the world.
In developing the guidelines, a systematic literature
search of MEDLINE, EMBSE, Cochrane Library, and
PubMed was conducted. The treatment recommendations
in these clinical guidelines were determined by the consen-
sus of the committee. The draft guidelines were available for
physician comments at the annual meetings of the Japan
Osteoporosis Society in 2010 and 2011.
The funding for all costs to produce the guidelines and
this position paper was obtained from the Japan Osteoporo-
sis Society, Japanese Society for Bone and Mineral Re-
search, and Japan Osteoporosis Foundation. All of the
authors state they have no conflict of interest related to the
guidelines or this position paper.
Definition, epidemiology, and etiology
Definition
The United States National Institutes of Health (NIH) Con-
sensus Development Conference on Osteoporosis Preven-
tion, Diagnosis, and Therapy held in 2000 proposed a new
definition of osteoporosis as follows: Osteoporosis is de-
fined as a skeletal disorder characterized by compromised
bone strength predisposing a person to an increased risk of
fractures. Further, it was stated that bone strength reflects
the integration of two main features: bone mineral density
(BMD), which accounts for almost 70 % of bone strength,
and bone quality, which accounts for the remaining 30 %.
Risk factors for fractures vary among individuals, and
include presence or absence of fragility fractures, family his-
tory, lifestyle factors, as well as BMD. Therefore, in clinical
practice, the risk of fracture should be comprehensively eval-
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Recently, some algorithms have been developed to quan-
titatively estimate an individual’s fracture risk by integrating
multiple risk factors (see “Risk factors for fracture” for
FRAX®).
Epidemiology
The estimated number of osteoporotic patients aged 40 or
over in Japan is 12,800,000 (3,000,000 men and 9,800,000
women), based on the result of a survey of the prevalence of
osteoporosis (diagnosed with BMD at the lumbar vertebrae
or proximal femur) stratified by age in the general popula-
tion (Fig. 1) [1] and the population structure stratified by age
groups in 2005. Furthermore, the estimated annual inci-
dence of osteoporosis, based on the BMD at the lumbar
vertebrae in the population aged between 40 and 79 years,
is 0.6 % in men and 2.3 % in women.
The estimated incidence of proximal femoral fractures
due to osteoporosis in Japan was 148,100 (31,300 men
and 116,800 women) in 2007 [2]. A follow-up study target-
ing a rural population revealed that the 10-year cumulative
incidence of vertebral fractures was 5.1 and 14 % for men
and women in their 60s, respectively, and 10.8 and 22.2 %
among men and women in their 70s, respectively [3]. How-
ever, a long-term trend shows that a later year of birth is
associated with a lower incidence of vertebral fractures.
The incidence of proximal femoral fractures was found to
be higher in western Japan than in eastern Japan. As com-
pared to reports from Western countries, the incidence of
proximal femoral fractures is lower and that of vertebral
fractures is similar or higher in Japan.
Etiology
From middle-age onward, BMD decreases and bone quality
deteriorates with advancing age, resulting in loss of bone
strength. Especially in women, BMD decreases sharply in
the perimenopausal period and for several years thereafter.
In addition to this natural course, genetic factors, nutritional
deficiency since childhood and puberty, lack of exercise,
and unhealthy lifestyle also cause loss of bone strength.
Primary osteoporosis is the clinical condition in which these
factors have caused a significant loss of bone strength.
Bone remodeling consists of bone resorption by osteo-
clasts and bone formation by osteoblasts, a mechanism to
maintain bone strength. If bone resorption increases with
advancing age and menopause and exceeds the rate of bone
formation, BMD will begin to decrease. Low BMD is
caused by activation of osteoclasts due to estrogen deficien-
cy associated with menopause, and by inadequate secondary
mineralization, microarchitecture deterioration, and a de-
crease in capacity for absorbing calcium associated with
advancing age, among other factors (Fig. 2).
Inadequate secondary mineralization and microarchitec-
ture deterioration result in deterioration of bone quality,
which is, however, also affected by the cell function of
synthesizing bone matrix, conditions surrounding bone ma-
trix (i.e., levels of oxidation and glycation), and levels of
vitamins D and K. When oxidative stress and glycation
increase in association with aging and lifestyle-related dis-
eases, the non-enzymatic (nonphysiological) cross-links
(see “Prevention of falls”) increase between collagen mole-
cules in the bone matrix, resulting in a loss of bone strength
(Fig. 2).
Prognosis
Fractures associated with osteoporosis, in particular proxi-
mal femoral fractures, lead to impairment in mobility and
vital functions and an increase in mortality. The relative risk
of overall mortality is high in older women with a low BMD
and vertebral deformity, and the greater the number of
vertebral fractures, the higher the risk of mortality. De-
creased BMD at the proximal femur increases the long-
Fig. 1 Estimated prevalence of
osteoporosis in Japan.
Osteoporosis was diagnosed
from BMD at vertebrae L2–4 (a)
and proximal femur (b). Data
from Yoshimura [1]
(Copyright© 2009 Springer
Science + Business Media BV)
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term mortality risk, regardless of the presence or absence of
vertebral fracture.
According to a survey on quality of life (QOL), patients
with osteoporosis score lower on factors related to posture/
body shape and falls/psychological in a self-assessment of
QOL than persons in the general population who have
undergone an osteoporosis screening.
Low BMD is strongly related to the Certification of
Needed Long-Term Care for the public nursing-care insur-
ance system in Japan. That is, osteoporosis or low BMD is
one of the most significant factors for becoming fragile/
immobilized or even becoming bedridden or institutional-
ized. Therefore, prevention of osteoporotic fractures is like-
ly to prevent reduced mobility or immobilization.
Diagnosis
Diagnostic procedures
The procedures for diagnosis of osteoporosis are shown in
Fig. 3 [4].
For the diagnosis of osteoporosis, a medical interview,
physical examination, diagnostic imaging, and blood and
urine examinations (including measurement of bone meta-
bolic markers) should be conducted first. Then, bone assess-
ment must be conducted with bone mass measurement and
spinal radiography. Based on this information, diseases
causing low bone mass or secondary osteoporosis should
be excluded, and then an accurate diagnosis of primary
osteoporosis should be made based on the diagnostic criteria
(see “Diagnostic criteria for primary osteoporosis”).
Information obtained in the diagnostic process about
factors that could contribute to osteoporosis and the risk
factors for fractures (e.g., family history, prevalent
fractures, and bone metabolic markers) should be used
to evaluate the severity of osteoporosis and the fracture
risk. This information will also be useful to provide
guidance about lifestyle modification and to select the
optimal therapeutic strategy.
Clinical presentation
In the absence of a fracture, osteoporosis is nearly asymp-
tomatic. However, patients with osteoporosis are predis-
posed to the development of fractures due to loss of bone
strength, and the occurrence of fractures will severely impair
their QOL (Fig. 4). Osteoporotic fracture is also called
fragility fracture.
Proximal femoral fractures directly lead to decreases in
the activities of daily living (ADL) and can lead to patients
being bedridden, resulting in poor prognosis.
The estimated prevalence of vertebral fractures in Japa-
nese in their early 70s is 25 % and is 43 % in person over
80 years old. The occurrence of vertebral fractures often
leads to subsequent vertebral fractures. Since a vertebral
deformity persists after the fracture heals, accumulation of
vertebral fractures in multiple sites causes kyphosis (round
back). Progressive kyphosis leads to deterioration of QOL
due to significantly limited ADL and lumbar backache, and
can cause functional declines or disorders of the digestive,
respiratory, and cardiac systems.
Some lifestyle-related diseases which cause atherosclero-
sis such as diabetes mellitus (DM), hypertension, dyslipide-
mia, and chronic kidney diseases (CKD) have attracted
attention in relation to osteoporosis. In particular, DM and
CKD predispose patients to osteoporosis, and increase their
fracture risk (see “Prevention of falls”). The possibility of
hidden osteoporosis always should be considered during
medical care of patients with lifestyle-related diseases.
Fig. 2 Factors causing
deterioration of bone strength
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Medical interview and physical examination
The objectives of the medical interview and physical exam-
ination are to assess the presence and symptoms of osteo-
porotic fractures, risk factors for osteoporosis and fractures,
and to obtain information for the differential diagnosis.
Family history of proximal femoral fractures (in either or
both parents), loss of height (4 cm or more relative to the
height at 25 years of age), current smoking, and excessive
alcohol consumption (3 units/day or more, 1 unit08–10 g
ethanol) are particularly important risk factors for osteopo-
rotic fractures. Therefore, taking a careful history including
these factors is needed. History of glucocorticoids use,
rheumatoid arthritis, and lifestyle-related diseases such as
diabetes mellitus are important information for the differen-
tial diagnosis.
In regard to the physical findings, a rounded back, fewer
than 20 teeth, and a value of less than −4 on the Female
Osteoporosis Self-Assessment Tool for Asians are key fac-
tors that strongly suggest osteoporosis.
Fig. 3 Procedure for the
diagnosis of osteoporosis. YAM
young adult mean (20 to
44 years of age). Adapted from
Orimo [4] (Copyright© 2001
Springer Science + Business
Media BV)
Fig. 4 Clinical presentation
and prognosis of osteoporosis
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Bone assessment
It is recommended that BMDs of the lumbar spine and/or
proximal femur are measured by dual-energy X-ray absorp-
tiometry (DXA). When there is a fracture or deformity in the
lumbar vertebrae that increases the influence of an artifact
on spine BMD, the data of lumbar spine should not be used.
If the measurement at either of these sites is not successful
(because of bilateral hip surgery, multiple fractures of the
lumbar vertebra, severe vertebral deformity, or excessive
obesity, etc.), another choice is forearm bone.
Microdensitometry has been developed in Japan to radio-
logically assess BMD, mainly of cortical bone in the second
metacarpal.
The speed of sound and broadband ultrasound attenua-
tion through bone are measured with quantitative ultrasound
(QUS). This is a non-invasive measurement technique and
may provide reliable information on bone quality along with
the BMD. However, it is easily affected by measurement
conditions, among other factors. The parameters used in
QUS were standardized by the QUS Standardization Com-
mittee of the Japan Osteoporosis Society in 2010 [5].
Fracture evaluation
Radiography of the thoracic and lumbar vertebrae are essential
for assessment of fracture, deformity, or change in the verte-
brae, and for exclusion of other similar disorders that present
with lower back pain, round back, or low bone mass. In the
Japanese diagnostic criteria, the presence of fragility fractures
alone confirms the diagnosis of osteoporosis (see “Diagnostic
criteria for primary osteoporosis”). Since most of the prevalent
fragility fractures, however, are vertebral fractures, usually
without pain, radiography is fundamental for their proper
diagnosis. Either semiquantitative assessment or quantitative
morphometry is used. The lateral DXA images for vertebral
fracture assessment can be used, but more clinical experience
in Japan is needed to make a recommendation.
If used during the early period after a fracture has oc-
curred (within 2 weeks), MRI provides a better diagnostic
yield than plain radiography. MRI is helpful particularly for
fresh vertebral fractures, because the height of the vertebral
body often does not decrease in the early period. Since it is,
however, impractical to diagnose all the cases with MRI,
MRI is recommended when it is necessary to distinguish
osteoporotic fractures including non-vertebral fractures
from those caused by other diseases, or for a detailed exam-
ination regarding complicating diseases.
Bone metabolic markers
The increase of bone metabolic markers is a BMD-
independent predictor of fractures, and bone metabolic
markers are one of the indices of fracture risk. There are
two types of bone metabolic markers: bone resorption
markers and bone formation markers. Examinations of
blood or urine for these bone metabolic markers easily
provide information on the bone metabolic state (Fig. 5) [6].
Bone metabolic markers are useful particularly for the
following situations. (1) The patient has little understanding
of the need for treatment. (2) The patient is scheduled to
receive pharmacotherapy. (3) It is difficult to decide what
drug to choose. (4) You want to adopt an appropriate treat-
ment for the patient’s pathological condition. Bone metabol-
ic markers are also useful for evaluation of the response to
treatment. Thus, it is recommended to measure them at the
time of diagnosis if possible.
Among bone metabolic markers, undercarboxylated
osteocalcin (ucOC) can be used as an index of vitamin K
deficiency in the bones.
When the values of bone resorption markers are abnor-
mally high, the presence of other metabolic bone diseases is
suspected.
Differential diagnosis
The targets of differentiation from primary osteoporosis are
secondary osteoporosis and other bone-related diseases.
Secondary osteoporosis is caused by other diseases or treat-
ments, but its clinical state can seem similar to that of
primary osteoporosis, while other bone-related diseases dis-
play a clinical state that is different from that of primary
osteoporosis. Some instances of secondary osteoporosis and
other bone-related diseases are critical or require immediate
medical attention. Further, most types of secondary osteo-
porosis require a therapeutic strategy different from that for
primary osteoporosis, and the appropriate treatment of the
causative diseases may lead to a dramatic improvement in
secondary osteoporosis. Therefore, the differential diagnosis
is an extremely important process, despite the prevalence of
secondary osteoporosis being low. The probability of sec-
ondary osteoporosis is relatively high among premenopaus-
al women and men.
Information for the differential diagnosis can be obtained
in every step of the diagnostic process. In the medical
interview, thorough medical and surgical histories are need-
ed, including current medications. Radiography may be
useful for exclusion of osteomalacia and bone metastases
of malignant tumors. Various causative states of secondary
osteoporosis may be suspected by the results of blood and
urine examinations, for example, hypercalcemia, hypocal-
cemia, elevated alkaline phosphatase level, and proteinuria.
It is usually considered that patients who visit specialized
medical institutes, such as university hospitals, are likely to
have secondary osteoporosis due to endocrine diseases and
others.
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Diagnostic criteria for primary osteoporosis
After excluding both the presence of other diseases character-
ized by low bone mass and the possibility of secondary
osteoporosis, primary osteoporosis should be diagnosed by a
two-step approach: (1) presence or absence of fragility frac-
tures and (2) BMD or assessment of osteopenia on spinal
radiography (Fig. 6) [4].
Primary osteoporosis is diagnosed on the presence of any
fragility fractures (defined as a nontraumatic bone fracture
caused by slight external force to a bone with low bone mass,
which correlates to a BMD<80 % of young adult mean
(YAM) or radiographic osteopenia of the spine) at sites in-
cluding spine, proximal femur, and the distal end of radius. If
there is no fragility fracture, the BMD level is used to diagnose
the patient as “normal”, “decreased bone mass”, or “osteopo-
rosis”. Evaluation of osteopenia based on spinal radiography
should be used as supplementary means, and quantitative
bone densitometry is preferable for bone assessment.
The T-score to YAM of BMD, not the percentage, is used
as diagnostic criteria internationally. A T-score of −1.5 rep-
resents a value of −1.5 standard deviation of the YAM and is
approximately equivalent to 80 % of the YAM in Japan. AT-
score of −2.5 is approximately equivalent to 70 % of the
YAM. Internationally, the proximal femur is considered to
be the standard measurement site for BMD.
Risk factors
Risk factors for fracture
Major risk factors for osteoporotic fractures are female
gender, advanced age, low BMD, and prevalent fractures.
In addition, many other factors affect fracture risk directly or
indirectly. Although a poor intake of calcium increases
fracture risk via low BMD, other risk factors for fractures
such as age, prevalent fracture, family history of fractures,
smoking, and drinking are independent of BMD. Low body
weight also is a BMD-independent risk factor, but only for
proximal femoral fractures.
Fig. 5 Measurement of bone metabolic markers in drug treatment of
osteoporosis. #1: in patients taking bisphosphonates, measure after stop-
ping drug for at least 6 months, and in patients taking other osteoporosis
drugs, measure after stopping drug for at least 1 month. #2: measure one
type each of a resorption marker and formation marker. #3: excluding
eldecalcitol. #4: in patients expected to be on long-term bisphosphonate
therapy, measure bone resorption markers and BAP or P1NP. Nishizawa
[6] (Copyright© 2012 Springer Science + Business Media BV)
Fig. 6 Diagnostic criteria for primary osteoporosis (updated in 2000).
Primary osteoporosis is diagnosed according to these criteria in the absence
of diseases causing low bone mass or secondary osteoporosis. #1: fragility
fracture is a nontraumatic bone fracture that is caused by slight external
force to a bone with low BMD (BMD less then 80 % of YAM). Sites of
fracture include the spine, proximal femur, and the distal end of the radius.
#2: BMD usually refers to lumbar BMD. However, when the measurement
is inappropriate for reasons such as spinal deformity, the proximal femur
BMD should be used. When measurement at those sites is difficult, BMD
of the radius, second metacarpal bone, or calcaneus will be used. Revision
of additional T-scores is under consideration. Adapted from Orimo [4]
(Copyright © 2001 Springer Science + Business Media BV)
Arch Osteoporos (2012) 7:3–20 9
The FRAX® (Fracture Risk Assessment Tool) was de-
veloped to estimate the 10-year probability of fractures in
individual patients by the World Health Organization
(WHO) in 2008 based on 11 risk factors identified from
worldwide data in ten cohorts. FRAX is a convenient tool to
easily identify a person at high risk for fractures, and there-
fore has been incorporated into the criteria for initiation of
pharmacological treatment in the present guidelines (see
“Criteria for initiation of pharmacological treatment”).
Prevention
Primary prevention of osteoporosis
The most important measure for primary prevention of
osteoporosis is education appropriate to each age group: in
early life to acquire as high a peak bone mass (PBM) as
possible, to maintain acquired PBM through exercise there-
after, and to minimize its decrease after menopause.
A study on the age-specific distribution of bone mass in
Japanese women revealed that PBM is achieved at 18 years
of age [7]. Thus, before age 18 is the most effective time for
physicians to encourage young people to increase PBM to
its maximal level. Guidance on maintenance of adequate
weight, active intake of calcium, and weight-bearing exer-
cise is effective.
For middle-aged and older persons, guidance on mainte-
nance of adequate weight, aerobic exercises especially walk-
ing, and weight-bearing exercise is effective. Smoking
cessation and limiting alcohol intake to less than 3 units/day
(1 unit08–10 g ethanol) is likely to decrease the fracture risk.
Prevention of falls
Most proximal femoral fractures in elderly people occur
because of a fall. Risk factors for proximal femoral fractures
are a past history of falls and the number of falls, and fall-
related factors including generalized weakness, paralysis,
muscular weakness, use of sleep-inducing drugs, and de-
creased vision.
Approaches to prevent falls include (1) exercise interven-
tions (e.g., training to increase strength of muscle, balance,
walking ability, and flexibility); (2) non-exercise interven-
tions (e.g., instruction about medication, diet, and environ-
ment, along with education and guidance for behavior
modification); and (3) multifactorial intervention (e.g., in
addition to 1 and 2, an individualized approach based on
the physical and mental functioning, environment, and med-
ical assessment of a patient).
In elderly people, vitamin D deficiency increases the risk
of falls, and administration of vitamin D can reduce the
frequency of falls.
Wearing a hip protector is effective for the prevention of
proximal femoral fractures; especially in high-risk groups in
elderly care facilities.
Osteoporosis screening
Osteoporosis screening is spreading as a part of the Elderly
Health Services (currently as a project under the Health Pro-
motion Law) in Japan, and is performed every 5 years in
women from 40 to 70 years old. The screening rate (the
percentage of women who underwent osteoporosis screening
against the entire target female population) was 4.6 % in 2005.
Osteoporosis screening for people of middle and older age
is aimed at early detection of asymptomatic osteoporotic
patients and persons at risk of osteoporosis to prevent future
fractures. Persons at risk of osteoporosis should be given
guidance on diet and exercises, and asymptomatic patients
should be targets for early intervention (secondary prevention).
In screening, persons should be classified as either
“Complete examination required”, “Guidance required”, or
“No apparent abnormality” based on the results of the med-
ical interview and bone mass measurement (Fig. 7) [8]. The
criteria for requiring a complete examination is a bone mass
of less than 80 % of YAM; this is different from the diag-
nostic criteria for osteoporosis (i.e., when BMD is less than
70 % of YAM in the absence of fragility fracture). In
addition, bone mass measurement at the calcaneus (includ-
ing QUS), which is not used to diagnose osteoporosis, is
also permitted in the screening. The reason for these differ-
ences is that screening should identify the persons requiring
the full diagnostic assessment for osteoporosis.
FRAX® will become suitable for osteoporosis screening
after the cutoff values for fracture probability are established
for complete examination and for guidance.
Treatment
Criteria for initiation of pharmacological treatment
The goals of osteoporosis treatment are prevention of frac-
ture as a complication and maintenance of good skeletal
health. Important strategies to reduce the fracture risk in
osteoporotic patients are treatment with a bone resorption
inhibitor or bone formation stimulant and guidance to es-
tablish a lifestyle that leads to maintenance and enhance-
ment of bone strength and to avoid risk factors for fractures,
such as a fall, that are independent of a decrease in bone
strength.
The risk factors for fracture include low BMD, factors
that contribute to a decrease in BMD, and deterioration of
bone matrix, including lifestyle-related diseases. A preva-
lent fragility fracture is the most important among all these
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factors with the exception of low BMD. Family history of
proximal femoral fractures significantly increases the frac-
ture risk even in persons without a fragility fracture who
have a “low bone mass” based on their BMD.
Based on this new knowledge about risk factors and the
consideration about using FRAX® (see “Risk factors for
fracture”), the criteria for initiating pharmacological treat-
ment to prevent fragility fracture was established as shown
in Fig. 8. In these criteria, FRAX® is used to consider
whether or not to initiate pharmacological treatment in per-
sons without a fragility fracture who have a low bone mass.
This is because persons with a fracture risk comparable to
patients with osteoporosis possibly could be included in this
group and need other measures to assess the magnitude of
the fracture risk other than low BMD. Considering that the
10-year probability of major osteoporotic fractures in the
patients receiving pharmacological treatment was observed
around 15 % in Japanese clinical settings, we adopted 15 %
as a treatment threshold for the persons with low bone mass.
In the guidelines, FRAX® is not used in the first-line
screening to determine the persons who need further exam-
ination such as bone densitometry. As stated earlier, the
Fig. 7 Criteria for osteoporosis
screening. Risk factors for
osteoporosis: non-modifiable
factors: aging, sex (female),
race, family history, late men-
arche, early menopause, and
history of fracture. Modifiable
factors: deficiency of calcium,
vitamin D, and K; excess intake
of phosphorus and salt; exces-
sive calorie restriction; low
BMI; lack of physical activity
and sunlight; smoking; and ex-
cess intake of alcohol and cof-
fee Orimo [8]
Fig. 8 Criteria for initiation of pharmacological treatment. #1: this means
proximal femoral fracture and/or vertebral fracture caused by slight exter-
nal force after menopause in women and after age 50 in men. #2: this
means distal forearm, proximal humerus, pelvis, lower leg and/or rib
fracture caused by slight external force after menopause in women and
after age 50 in men. #3: revision of additional T-scores is under consider-
ation for some measurement sites. #4: this should be applied in persons
<75 years. Additionally, a lower cutoff value does not include all young
persons in and around their 50s for whom pharmacological treatment is
recommended based on the present diagnostic criteria. #5: as these criteria
refer to primary osteoporosis, they should not be applied to persons whose
FRAX® risk factors are “glucocorticoid”, “rheumatoid arthritis”, or “sec-
ondary osteoporosis”. That is, these criteria should be applied only in
persons who answer “No” to each of these items
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cutoff value for the screening in Japan is being studied. The
cutoff value of a 15 % 10-year probability is used for
women and men younger than 75 years old, because almost
all of the persons of this age group have a value above 15 %
and thus its power as a cutoff value is too weak.
Evaluation of response to treatment
The optimal method for bone mass measurement to evaluate the
therapeutic effect is DXA at the lumbar vertebrae on the ante-
roposterior direction, because it is sensitive enough to detect
changes in bone mass. If the bone mass cannot be measured
precisely at the lumbar vertebrae, measurement at the total hip is
recommended. The timing of measurement should be deter-
mined based on the least significant change of each method.
The efficacy of drugs with significant effects on bone
metabolism can be evaluated by measuring bone metabolic
markers. It is beneficial to measure bone resorption markers
at 3 to 6 months after the initiation of treatment and bone
formation markers every 6 to 12 months. Attention should
be paid to the minimum significant change of each marker.
Plain radiography is useful for detection of incident ver-
tebral fractures after the initiation of treatment. CT, MRI,
and bone scintigraphy are sometimes required for confirma-
tion of minor fractures, incomplete fractures, and unappar-
ent fractures, and for differentiation from other clinical
conditions including tumors.
QOL assessment using the Japanese Osteoporosis Qual-
ity of Life Questionnaire (JOQOL) is useful also for evalu-
ation of therapeutic effects.
Basic treatments (non-pharmacological treatment)
A daily intake of calcium (700 to 800 mg) is recommended
to optimize the effect of pharmacological treatment. It has
been reported that calcium derivatives and calcium supple-
ments may increase the risk of cardiovascular diseases.
However, dietary intake of the same amount of calcium
has not been shown to increase cardiovascular risk. More-
over, those adverse findings were reported from outside
Japan, where calcium intake, serum lipid levels, and BMI
are different from those in Japan. At this time, calcium as a
medicine or supplement should not exceed 500 mg per dose.
Vitamin D (recommended daily intake, 10 to 20 μg) and
vitamin K (250 to 300 μg) are also essential, and they
should be prescribed to be taken as a medicine when it is
difficult for the patient to obtain a sufficient amount from
dietary sources. Hyperhomocysteinemia due to vitamin de-
ficiency (vitamins B6, B12, and folic acid) involved in
homocysteine metabolism has been shown to be a BMD-
independent risk factor for fracture. It is recommended to
warn patients not to consume excessive amounts of phos-
phorus, salt content, caffeine, and alcohol.
It has been demonstrated that high-impact activities, re-
sistance exercises, back muscle exercises, stretching exer-
cises, aerobic exercises, walking, and balance training can
increase BMD and prevent vertebral fractures and falls in
patients with osteoporosis.
In terms of pain relief, few data from randomized con-
trolled trials are available about the effects of various phys-
ical therapies, nerve blocks, and surgeries; however, the
efficacy of some drugs has been demonstrated.
Pharmacological treatment
These Guidelines detail the effect of each therapeutic agent
used in Japan on BMD and the risk of vertebral fracture, non-
vertebral fracture, and proximal femoral fracture, based on
evidence from Japan and abroad. Each recommendation is also
graded (Table 1). In regard to some therapeutic agents, the
effect on QOL is also described. Table 2 shows the prescription
drugs covered by the public health insurance in Japan.
For the selection of therapeutic agents, the full range of
drug-related information must be considered: the efficacy of
each medicine on BMD, fracture risk, QOL including pain,
bonemetabolicmarkers, risk of fall, as well as safety, including
effects other than those on bone metabolism per se and adverse
effects. Further, the patient’s clinical state must be considered.
The systematic review published by MacLean and col-
leagues indicated that bisphosphonates (alendronate and risedr-
onate) are a first-line agent for patients at high risk of vertebral,
non-vertebral, or proximal femoral fracture [9]. Parathyroid
hormone derivatives are first-line agents for patients at high
risk of vertebral or non-vertebral fracture. Selective estrogen
receptor modulators (SERMs) are first-line agents for patients
at high risk of vertebral fracture. Minodronic acid, a bisphosph-
onate developed in Japan, is expected to be used for the high-
risk group for vertebral fracture. Eldecalcitol, an active vitamin
D3 derivative developed in Japan, is expected to be used for the
high-risk group for vertebral or non-vertebral fracture. Howev-
er, more data are required for these new agents.
Estrogen derivatives
A postmenopausal decrease in bone mass is caused by
estrogen deficiency. Therefore, estrogen replacement has
been considered to be an effective treatment option for
osteoporosis since early times. Estrogen replacement is use-
ful also for prevention and treatment of other diseases and
symptoms caused by estrogen deficiency. Administration of
estrogen to young amenorrheic women or relatively young
postmenopausal women can prevent osteoporosis. Estrogen
is also useful for treatment of osteoporosis in women with
climacteric symptoms in relatively early stage of postmeno-
pause. Conjugated estrogen, estradiol, and estriol are the
approved estrogen derivatives in Japan.
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Table 1 Grading of recommendation of therapeutic agents for osteoporosis in Japan
Therapeutic agent BMD Vertebral fracture Non-vertebral fracture Proximal femoral fracture
Calcium Calcium L-aspartate hydrate C C C C
Dibasic calcium phosphate hydrate C C C C
Estrogen Estriol C C C C
Conjugated estrogensa A A A A
Estradiol A C C C
Active vitamin D3 Alfacalcidol B B B C
Calcitriol B B B C
Eldecalcitol A A B C
Vitamin K2 Menatetrenone B B B C
Bisphosphonate Etidronate disodium A B C C
Alendronate sodium hydrate A A A A
Sodium risedronate hydrate A A A A
Minodronic acid hydrate A A C C
SERM Raloxifene hydrochloride A A B C
Bazedoxifene acetate A A B C
Calcitoninb Elcatonin B B C C
Calcitonin (Salmon) B B C C
PTH Teriparatide (genetical recombination) A A A C
Other drugs Ipriflavone C C C C
Nandrolone decanoate C C C C
A strongly recommended to use, B recommended to use, C not enough evidence to recommend use, D recommended not to use
a Administration of conjugated estrogen for osteoporosis is not covered by the public health insurance in Japan
b Calcitonin has an analgesic effect, and reduces pain due to osteoporosis (grade A)
Table 2 Prescriptions of anti-
osteoporotic agents covered by
the public health insurance in
Japan (as of September 2011)
Teriparatide acetate, a new drug
developed in Japan, came to
market in November 2011. Pre-
scription is 56.5 μg/w, s.c., up to
72 weeks
aAgents developed in Japan
Generic name Launched Prescription for osteoporosis
Calcium L-aspartate hydrate 1968 1.2 mg/day, p.o.
Dibasic calcium phosphate hydrate 1985 3 g/day, p.o.
Estriol 1969 1 mg/day, p.o.
Conjugated estrogens 1999 Not covered by the public insurance
Estradiol 2008 1 mg/day, p.o.
Alfacalcidol a 1981 0.5 or 1 μg/day, p.o. (adult)
Calcitriol 1986 0.5 μg/day, p.o.
Eldecalcitola 2011 0.75 or 0.5 μg/day, p.o.
Menatetrenonea 1995 45 mg/day, p.o.
Etidronate disodium 1990 200 or 400 mg/day, p.o. (intermittent)
Alendronate sodium hydrate 2001 5 mg/day or 35 mg/w, p.o.
Sodium risedronate hydrate 2002 2.5 mg/day or 17.5 mg/w, p.o.
Minodronic acid hydrate a 2009 1 mg/day or 50 mg/4w, p.o.
Raloxifene hydrochloride 2004 60 mg/day, p.o.
Bazedoxifene acetate 2010 20 mg/day, p.o.
Elcatonina 1982 20 IU/w, i.m.
Calcitonin (Salmon) 1990 20 IU/w, i.m.
Teriparatide (genetical recombination) 2010 24 μg/day, s.c. (up to 24 months)
Ipriflavone 1988 200 mg/day, p.o.
Nandrolone decanoate 1984 25 or 50 mg/3 w, i.m.
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Although conjugated estrogen increases BMD and pre-
vents vertebral, non-vertebral, and proximal femoral frac-
ture, it is not covered by the public health insurance in Japan
for the treatment of osteoporosis.
Estradiol increases BMD, but there is little evidence that
it prevents fractures.
There is almost no evidence about the effects of estriol.
Alfacalcidol and calcitriol (active vitamin D3 derivatives)
Alfacalcidol and calcitriol are active vitamin D3 derivatives.
Alfacalcidol, developed in Japan, is a prodrug requiring hy-
droxylation in the liver for activation. Because these deriva-
tives were approved for the treatment of osteoporosis in 1983
and 1989, respectively, there is insufficient large clinical trial
data. However, several reports suggested these agents main-
tain lumbar BMD at a significantly higher level as compared
to placebo, or reduce the risk of vertebral and non-vertebral
fractures (not statistically significant; Fig. 9a) [10].
It has been reported also that vitamin D deficiency causes
atrophy of the type II muscle fibers, and that vitamin D
supplementation improves trunk imbalance. Active vitamin
D3 derivatives (alfacalcidol and calcitriol) reduce falls among
the elderly (Fig. 9b) [11]. These active vitamin D3 derivatives
have been confirmed to be safe, even for long-term use, and
they are recommended for the elderly (see “Combination
therapy” for combination with bisphosphonate).
Eldecalcitol (active vitamin D3 derivative)
Although the conventional active vitamin D3 derivatives
have been reported to be effective for preventing fractures,
they have not been shown to increase BMD significantly.
Various vitamin D3 derivatives have been investigated; of
these eldecalcitol was developed in Japan. Eldecalcitol
showed superior efficacy to alfacalcidol to increase BMD
(Fig. 10a) [12], while its effect on calcium absorption was
nearly unchanged. Eldecalcitol may exert its actions by
Fig. 9 Meta-analyses on the efficacy of vitamin D. a Relative risk for
vertebral fractures after treatment with vitamin D. RR relative risk, CI
confidence interval. Open rhombus indicates using calcitriol and
closed rhombus using alfacalcidol. Adapted from Papadimitropoulos
[10] (Copyright© 2002 The Endocrine Society). b Compared risk of
falling between vitamin D-treated group and control group. OR odds
ratio, CI confidence interval. Adapted from Bischoff-Ferrari [11]
(Copyright© 2004 American Medical Association)
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promoting calcium absorption from the small intestine, sim-
ilar to the conventional active vitamin D3 derivatives, and
prevent bone resorption by inhibiting osteoclastic function.
In a comparative study of eldecalcitol and alfacalcidol, the
incidence of vertebral fractures was found to be significantly
lower in the eldecalcitol group (Fig. 10b) [12]. While there was
no significant difference in the overall incidence of non-
vertebral fractures between the eldecalcitol and alfacalcidol
groups, there was a trend towards a greater decrease in the
incidence of non-vertebral fractures at the three major sites
(humerus, wrist, and hip) in the eldecalcitol group than in the
alfacalcidol group (Fig. 10c) [12]. Of note, the incidence of wrist
fractures was significantly reduced in the eldecalcitol group.
Clinical trials of eldecalcitol have been conducted in patients
over a wide range of age and severity, and this agent can be
used across the entire spectrum of patients with osteoporosis.
Menatetrenone (vitamin K2 derivative)
In elderly women and patients with osteoporosis being
treated with a bisphosphonate, insufficient intake of vitamin
K is a BMD-independent risk factor for fractures. Menate-
trenone, a vitamin K2 derivative, promotes carboxylation of
osteocalcin, and thereby it reduces the serum level of ucOC,
an index of vitamin K deficiency.
Menatetrenone slightly increases lumbar BMD and
reduces vertebral and non-vertebral fractures (Fig. 11)
[13]. Menatetrenone is considered to exert its fracture-
reducing effect via a mechanism of action other than in-
creasing BMD.
Etidronate (bisphosphonate)
Notably, for etidronate, a first-generation bisphosphonate, there
is a small margin between its serum level for the onset of its
inhibitory actions on bone resorption and the serum level for its
inhibitory effects on bone formation. Close attention must be
paid to its narrow safety range. Thus, a cyclical intermittent
treatment strategy (200 to 400 mg/day once daily for 2 weeks,
followed by a rest period of 10 to 12 weeks) is essential.
Because etidronate reduces bone resorption, it is effective
particularly for high-turnover osteoporosis, and it maintains
bone mass even in low-turnover osteoporosis. Etidronate
reduces blood and urine levels of bone metabolic markers.
Etidronate reduces incident vertebral fractures in patients who
have vertebral fractures. There is no clear evidence about
whether or not etidronate reduces non-vertebral fractures.
Alendronate (bisphosphonate)
Alendronate, a second-generation bisphosphonate, has a very
wide safety range. Its inhibitory effect on bone resorption is
exerted at a much smaller dose than the dose for its inhibitory
effect on bone formation (approximately 1/6,000).
Fig. 10 Effect of eldecalcitol compared with alfacalcidol. a Change in
lumbar BMD. Data are mean ± SE, *p<0.001 vs alfacalcidol group by
Student t test (Matsumoto [12] (Copyright© 2011 Elsevier)). b Incidence
of vertebral fracture. Hazard ratio (HR) is 0.74 and 95 % confidence
interval (CI) is 0.56–0.97. Data from Matsumoto [12] (Copyright© 2011
Elsevier). c Incidence of non-vertebral fractures. HR for three major non-
vertebral fractures is 0.52 and 95 % CI is 0.29–0.93, p00.031. Three
major non-vertebral sites mean humerus, wrist, and hip, i.e., the three sites
of major non-vertebral fractures recognized as osteoporotic fractures in
FRAX®. HR for wrist fractures is 0.29 and 95 % CI is 0.11–0.77, p0
0.005. Data from Matsumoto [12] (Copyright© 2011 Elsevier) and the
website of Pharmaceuticals and Medical Devices Agency (in Japanese)
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Many clinical trials and meta-analyses have shown that
alendronate increases BMD, reduces fractures at the verte-
bra/non-vertebra, proximal femur, and distal end of the
forearm; and improves the bone metabolic marker profile.
Alendronate has been reported to reduce vertebral fracture
and increase lumbar BMD also in men with osteoporosis.
In terms of QOL, a decrease in the duration of bed rest for
low back pain, a decrease in the days of activity restriction,
and improvement of arthralgia and pain-related QOL scores
after treatment with alendronate have been reported (see
“Combination therapy” for the combination with active
vitamin D3 derivatives).
A once-weekly dose of alendronate (35 mg), compared to
a daily dose of alendronate (5 mg) was shown to have a
similar effect on lumbar BMD and urinary levels of type I
collagen cross-linked N-telopeptides (NTX); the incidence
of adverse reactions and drug discontinuation was lower in
the once-weekly group.
Risedronate (bisphosphonate)
Risedronate, a third-generation bisphosphonate, has a strong
inhibitory effect on bone resorption.
Many clinical trials and meta-analyses have shown that
risedronate increases BMD and reduces fractures at the
vertebra/non-vertebra and proximal femur in postmenopaus-
al women. Risedronate was reported to increase lumbar
BMD also in men with osteoporosis. Large-scale clinical
trials in North America, Europe, and Australia have shown
preventive effects with risedronate against incident vertebral
fracture from the first year of treatment. In Japan, it was
reported that risedronate improved scores for body pain,
vitality, and social functioning in QOL assessment using
the SF-36 scale.
Once-weekly risedronate (35 mg), compared to daily
risedronate (5 mg), was shown to increase BMD at the
femoral neck and trochanter to the same degree in a study
in the USA. In a Japanese clinical trial, once-weekly risedr-
onate (17.5 mg), compared to daily risedronate (2.5 mg),
increased lumbar BMD to the same degree at 48 weeks.
Minodronic acid (bisphosphonate)
Minodronic acid is the only domestically developed
bisphosphonate for osteoporosis, and the only bisphosphonate
which has been investigated for its inhibitory effect on fracture
in Japanese patients at doses approved in Japan. Minodronic
acid has the strongest inhibitory effect on bone resorption
among the bisphosphonates currently available in Japan.
The efficacy of minodronic acid on BMD at the lumbar
spine and total hip is equivalent to alendronate (Fig. 12a)
[14]. In addition, minodronic acid significantly increased
BMD in patients who had a poor response to other
bisphosphonates.
Minodronic acid reduced vertebral fracture risk by 59 % in
Japanese patients with osteoporosis (Fig. 12b) [15], and no
Fig. 11 Meta-analysis on the efficacy ofmenatetrenone on fractures.OR odds ratio,CI confidence interval (Cockayne [13] (Copyright© 2006American
Medical Association))
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difference was observed in the effect between patients above
and below 75 years of age. No clinical trial to determine the
effect of minodronic acid on non-vertebral fracture or proxi-
mal femoral fracture has been conducted. The results of the
ongoing Japanese Osteoporosis Intervention Trial (JOINT)-04
initiated in 2011 by the Adequate Treatment of Osteoporosis
(A-TOP) Research Group (see “Combination therapy”) are
greatly anticipated to answer these questions.Minodronic acid
is available for daily use (1 mg) and once every 4 weeks
(50 mg).
Raloxifene (SERM)
Raloxifene, a selective estrogen receptor modulator, binds to
the estrogen receptor (ER) with an affinity equivalent to
estrogen and induces a conformational change at the helix
12 in the C-terminal part of ER; this conformational change
produced by raloxifene is different from that produced by
estrogen. Thus, raloxifene has a tissue-selective pharmaco-
logical action: it shows estrogen-like effects on bone, but
not on the breast or uterus.
The Multiple Outcomes of Raloxifene Evaluation, a
large-scale randomized controlled trial with 7,705 patients
in 25 countries, demonstrated that raloxifene increased
BMD and reduced incident vertebral fractures, regardless
of the presence or absence of prevalent vertebral fractures
and even in subjects with low bone mass (osteopenia).
Additionally, raloxifene significantly reduced the incidence
of non-vertebral fractures in patients with severe vertebral
fractures. In Japan, a 3-year post-marketing surveillance
demonstrated that the overall incidence of clinical fractures
was as low as 1.2 %.
Many observational studies from Japan and abroad dem-
onstrated the effect of raloxifene on QOL, including pain
relief. A meta-analysis revealed that raloxifene decreases the
overall mortality by 10 %.
Venous thromboembolism is one of the clinically impor-
tant adverse events of SERMs. The incidence of venous
thromboembolism in patients treated with raloxifene is
0.2 %, stated in the drug package insert, based on the results
of a 3-year post-marketing surveillance conducted in 7,557
Japanese patients.
Bazedoxifene (SERM)
Bazedoxifene, a SERM, has an estrogen-like action selec-
tively on bone metabolism and lipid metabolism, but not on
the breast or uterus.
An international multi-center clinical trial demonstrated
that bazedoxifene increases BMD and reduces vertebral frac-
tures, similar to raloxifene. Although no overall reduction on
non-vertebral fractures was observed with bazedoxifene, the
incidence of non-vertebral fracture in postmenopausal women
at a higher risk of fracture was significantly reduced by
bazedoxifene as compared to placebo and raloxifene. Addi-
tionally, the higher the FRAX® score, the more effectively
bazedoxifene reduced osteoporotic fractures. Bazedoxifene
was also reported to improve the profile of bone metabolic
markers. The effect of bazedoxifene on proximal femoral
fracture has not been studied yet.
Fig. 12 Effect of minodronic
acid on BMD and vertebral
fracture. a Percent change in
lumbar spine and total hip
BMD. Solid line is minodronic
acid 1 mg (n0134) and broken
line is alendronate 5 mg (n0
135). Data are mean ± SE
(Hagino [14] (Copyright© 2009
Elsevier)). b Incidence of
vertebral fracture. Solid line is
minodronic acid (n0339) and
broken line is placebo (n0328).
Relative risk is 0.411 (95 %
confidence interval 0.267–
0.634) by Cox regression
model. *p<0.0001 by log-rank
test between the groups (Mat-
sumoto [15] (Copyright© 2009
Springer Science + Business
Media BV))
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A significant decrease in the incidence of vertebral frac-
tures and the safety of the drug were consistently observed
during the 5-year treatment with bazedoxifene.
Calcitonin derivatives
Calcitonin is a bone resorption inhibitor acting directly on
osteoclasts and pre-osteoclasts to control their functions.
Calcitonin also relieves pain via the central serotoninergic
system, and therefore its derivatives may be the first choice
to obtain pain relief and improves QOL in the early phase
after the occurrence of osteoporotic fractures or in patients
with postural distortion associated with vertebral fractures.
There are some reports on the effect of calcitonin deriv-
atives on BMD and vertebral fracture (Fig. 13a) [16], but
none on non-vertebral or proximal femoral fractures.
Some randomized clinical trials and systematic reviews
revealed significant reductions in the severity of pain asso-
ciated with ADLs 1 to 4 weeks after calcitonin was started
(Fig. 13b) [17]. In terms of QOL, improvement in SF-36
scores, pain relief, and improved ADLs, and an enhanced
effect of rehabilitation in patients who had a total hip re-
placement after proximal femoral fracture was reported.
Outside of Japan, intra-nasal formulations of calcitonin
derivatives are used primarily, and a preventive effect on
fractures and beneficial effect on pain was observed. How-
ever, the increased risk of cancer was reported from the
European Medical Association (EMA) in patients treated
with calcitonin and intra-nasal calcitonin was withdrawn
from the European market.
Although antibodies might be produced after injection of
calcitonin derivatives, they do not influence the effect of
calcitonin and are not involved in the side effects of calci-
tonin derivatives. Therefore, patient monitoring is not
needed.
Teriparatide (recombinant human parathyroid hormone)
Unlike bone-resorption inhibitors, intermittent administra-
tion of teriparatide (a recombinant form) as a daily subcu-
taneous injection specifically increases serum P1NP, a bone
formation marker, indicating promotion of bone remodeling
followed by the formation of bone tissue.
Teriparatide, given as a daily subcutaneous injection, is
recommended in patients at high risk of fractures such as
patients who have had a fracture(s) while being treated with
a bisphosphonate or SERM, elderly patients with multiple
vertebral fractures or proximal femoral fractures, or patients
with significantly reduced BMD. The combination of teri-
paratide with an oral bisphosphonate is not recommended.
Teriparatide increases BMD at the lumbar vertebrae and
proximal femur, and reduces vertebral and non-vertebral
fracture. The incidence of a radial fracture is reduced with
teriparatide, while the apparent BMD of the radius is slight-
ly decreased in association with the formation of new bone
matrix, and the external diameter of the radius is increased.
A meta-analysis revealed that teriparatide reduces low back
pain.
Teriparatide (a recombinant form) approved in Japan is
self-injected daily at home, after instruction by physicians or
nurses. The total dosing period is limited to 24 months.
After 24 months of treatment with teriparatide, adequate
treatment with a bone-resorption inhibitor is recommended
to maintain the bone strength.
Fig. 13 Effect of elcatonin on BMD and pain associated with vertebral
fracture. a Percent change in lumbar spine BMD. Solid line is elcatonin
(20 units per week) with 0.6 g calcium lactate and broken line is control
(calcium lactate only). Data are mean ± SE. Numerals in parentheses
denote number of patients. Comparison within groups: Student’s paired
t-test, #p<0.05; between groups: Student’s unpaired t-test, *p<0.05.
Orimo H [16] (Copyright© 1996 Springer Science + Business Media
BV). b Percent change in pain associated with getting up evaluated
with visual analog scale (VAS). Solid line is elcatonin (20 units per
week, n044) and broken line is control (untreated, n042). Two-way
repeated-measures ANOVA, *p<0.05, **p<0.01, NS not significant.
Mann–Whitney U test, #p<0.05, ##p<0.01 (Nakano [17])
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Combination therapy
Osteoporosis is a multifactorial disease, thus combination
therapy with agents with different mechanisms of action is
considered reasonable. However, the efficacy of combina-
tion therapy lacks evidence at this time.
The Adequate Treatment of Osteoporosis (A-TOP) Re-
search Group was authorized in the year 2000 by the Japan
Society of Osteoporosis and assisted by the Public Health
Research Foundation to obtain clinical evidence regarding
osteoporosis treatment. It conducted a clinical trial compar-
ing monotherapy with alendronate, a new bisphosphonate at
the time, and combination therapy with alendronate and
alfacalcidol, an active vitamin D3 derivative developed in
Japan (Japanese Osteoporosis Intervention Trial: JOINT-
02). The incidence of vertebral fracture was significantly
reduced in the combination therapy group during the first
6 months of treatment, and in both subgroups of patients
with multiple vertebral fractures and grade 3 vertebral frac-
tures by semiquantitative assessment during the 2-year treat-
ment period (Fig. 14) [18]. The incidence of non-vertebral
fracture (weight-bearing bones) was also significantly re-
duced in the combination therapy group. Based on these
results, combination therapy with alendronate and an active
vitamin D3 derivative is recommended for the prevention of
incident vertebral and non-vertebral fracture in patients at a
high risk of fracture.
Secondary osteoporosis
Osteoporosis secondary to other diseases
Secondary osteoporosis is defined as decreased BMD and
deteriorated bone quality (pathologic state specific to oste-
oporosis) having one or more causes in addition to genetic
factors, lifestyle, menopause, and aging. Secondary osteo-
porosis that is caused by a disease, such as hyperparathy-
roidism, can be improved by treating the underlying disease.
Hyperparathyroidism can be classified into either prima-
ry hyperparathyroidism, a disorder of the parathyroid itself,
or secondary hyperparathyroidism, a pathological state sec-
ondary to other disorders, such as chronic kidney disease or
vitamin D deficiency/depletion. In both types of hyperpara-
thyroidism, excessively secreted parathyroid hormone pro-
motes bone turnover and consequently decreases the BMD,
resulting in an increased fracture risk. However, the thera-
peutic strategies employed for each type are entirely differ-
ent. Primary hyperparathyroidism is treated mainly by
parathyroidectomy, and there is no evidence regarding phar-
macologic treatment. Secondary hyperparathyroidism
improves with treatment of its underlying disease. Hyper-
parathyroidism secondary to CKD should be treated in
accordance with the Japanese Evidence-based Practice
Guideline for the Treatment of CKD.
In rheumatoid arthritis, bone resorption increases and
BMD decreases because of several factors, including acti-
vation of inflammatory cytokines, immobility, and use of
glucocorticoids. Consequently, the fracture risk increases.
Infliximab, an anti-TNF agent used to treat rheumatoid
arthritis, increases BMD in patients with osteoporosis sec-
ondary to rheumatoid arthritis. Among the useful therapeu-
tic medications for osteoporosis, bisphosphonates reduce
fracture risk.
Osteoporosis secondary to lifestyle-related diseases
In recent years, it was demonstrated that bone metabolism is
influenced by some atherosclerosis-inducing disorders such as
diabetes mellitus, dyslipidemia, hypertension, and chronic
kidney disease. In particular, osteoporosis caused by diabetes
mellitus or CKD is established as “osteoporosis secondary to
Fig. 14 Efficacy of
combination therapy with
alendronate and active vitamin
D3 on vertebral fracture. HR
hazard ratio of incident
vertebral fracture, CI
confidence interval (Orimo [18]
(Copyright© 2011 Informa
Plc.))
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lifestyle-related diseases”, bringing it special attention within
secondary osteoporosis. A vigorous assessment for osteopo-
rosis is recommended in patients with these diseases.
Osteoporosis secondary to lifestyle-related diseases is main-
ly associated with deterioration in bone quality, whereas BMD
is relatively well-preserved in most cases. Therefore, therapeu-
tic intervention in patients with diabetes mellitus or CKD
should be started as soon as “decreased bone mass” is identi-
fied, in accordance with the diagnostic criteria of osteoporosis.
The main cause of deterioration in bone quality in these
patients is thought to be altered cross-links among the col-
lagen molecules in bone tissue (nonphysiological collagen
cross-links, i.e., advanced glycation endproducts) due to an
increase in oxidative stress and acceleration of glycation.
While the therapeutic modality has not been established
yet, the benefit of alendronate, risedronate, raloxifene, and
parathyroid hormone derivatives has been reported in large
clinical trials. Pentosidine is likely to be a marker for bone
quality and is expected to be an index of the fracture risk.
Treatment-related osteoporosis
Glucocorticoid agents and sex hormone lowering therapy
are important causes of treatment-related osteoporosis.
Systemically administrated glucocorticoid decreases bone
mass and increases fracture risk, thus 50 % of patients under
long-term treatment with glucocorticoids suffer from osteopo-
rosis. In general, patients taking glucocorticoids at doses of
5 mg (prednisolone equivalent) or more per day for 3 months
or more should be assessed for bone mass and the need for
osteoporosis treatment. Moreover, it is recommended to start
treatment at higher BMD values than those used in the criteria
for treatment of primary osteoporosis. In Japan, a revision of
the 2004 “Guidelines on the management and treatment of
corticosteroid-induced osteoporosis” is being developed.
Even though guidelines currently recommend bisphosph-
onates for the treatment of glucocorticoid-induced osteopo-
rosis, generally they are not recommended for women
intending to become pregnant. Although teriparatide is
expected to increase bone mass, it is indicated only for
“osteoporosis with a high risk of fractures”.
Endocrine therapy (sex hormone lowering therapy) for
breast cancer and prostate cancer decreases BMD. Bisphosph-
onates can improve BMD in these patients, but there is no
evidence yet about its ability to reduce fracture risk.
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